{"name":"Lori Davis, MD","slug":"lori-davis-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Adjunctive asenapine","genericName":"Adjunctive asenapine","slug":"adjunctive-asenapine","indication":"Adjunctive treatment of bipolar I disorder in adults","status":"marketed"}]}],"pipeline":[{"name":"Adjunctive asenapine","genericName":"Adjunctive asenapine","slug":"adjunctive-asenapine","phase":"marketed","mechanism":"Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.","indications":["Adjunctive treatment of bipolar I disorder in adults","Adjunctive treatment of major depressive disorder in adults"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNbHk4UW1JRkVxUzJMeUNXUnVrcWR1NkY5ejZRdDFCaDl1b1dnTGNIZkprRkxtSk8zeWIyaUJDMkp6b09tdDlQR2ZhUXZQeVBBU3ZCRTRCRWFSeUd1ek4xRGxzMVFlSXNVVm05a2pSNmhkTlU4TVpMRmR0d21hX2t5Wm5GSVJmOHk1RlJrNnJqZnRtUEpqRV80NHhKbWtuZlJyQjVFd3hkdVpUSDZkWVhCQUxGSQ?oc=5","date":"2025-11-26","type":"trial","source":"Psychiatrist.com","summary":"The Goldilocks Problem: Balancing Internal Validity With Generalizability in Clinical Trials - Psychiatrist.com","headline":"The Goldilocks Problem: Balancing Internal Validity With Generalizability in Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQVkZpdGt3Mkk5T1QtaTk4S1lJQjlWRkxYUXg1S0YyUkVqeTc0NWVYODBEOEpSUUxNcHFyeEJvbGFqdC1wNVMyMEdtdUpDZjJLM1cxVmpCdFVXYXJyVEVMNEUzc3QzRU5JeVpUdHBXcjExWWgxVThibWlDN0x3NEh3b2NvLWJ6ZXltcF9Xdmg1SUNfZE9Tc1BFTTJXMkRKN2VFc2FvSU5mRE5BRkZjWkZ2ZWYzSFkxM1lQdGd2Qk5CMmRIT2hTRkpSNEo0aXlkWnAtTjRzaUc0M2FWSUJMMzFSR21FM05QYk1STG1pam1B?oc=5","date":"2025-02-19","type":"trial","source":"Psychiatrist.com","summary":"Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder: A Full-Factorial Randomized Clinical Trial - Psychiatrist.com","headline":"Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder: A Full-Factorial Rando","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPYWVNUXZMRTZSakRRdjM2SDZmdDZvTU4wU2doZ25oVll4cVNvNGFjRDhXMGNtejM0SldSVGJPLXJoR2ptdERpcDZRVkcyN2ZjZjJmeXgwLS1NWGpEdjhpZ1o5WHhDT3M5NnlJYjJHX19Ock55djB0YzlVZWN1bl9tMFZYVTBYSjkxVXMtLWNYTXZyMThfNHk2S056WDUzUXYtbW4tVHJFdHdWS0xOOXpubFNTc05KRGZRLTBQSnYtUF9hUEEy?oc=5","date":"2025-02-03","type":"pipeline","source":"Patient Care Online","summary":"Optimizing PTSD Treatment: The Role of Brexpiprazole and Sertraline in Future Guidelines - Patient Care Online","headline":"Optimizing PTSD Treatment: The Role of Brexpiprazole and Sertraline in Future Guidelines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPb2VKZHUxZE81NUFVTGhrSXlJYjRUNzBhU3hpOHFXYXpyNjJfSkpwd2NlRTZrWGM2azlET0VrNjEyTzBrMHBITmtRUWhiUG9HZHFER3BIYjN5WDdUT2gzbk05WVBoeTVZVGFzREprMnF1NTd5VG8yMkstcHBkT3Z5V2o0T1dGQTlHOU96WTJBRVAxdTZMWXJheFU0clplS2s?oc=5","date":"2024-12-20","type":"pipeline","source":"Medscape","summary":"Finally, a New Drug for Posttraumatic Stress Disorder? - Medscape","headline":"Finally, a New Drug for Posttraumatic Stress Disorder?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBjTVF6RnpMWkhrWmJGNFBta2ViOWozUmVWX2V1X1Q2RzVfdTM3bU52S1ZUSTBINU5sR2pSdEhhUklPZVBkLTRLM2FTM2lJRGdKZnhudTVnZE44UnNwSGtDN1ZhUGRvX1pKbWhnUU1Gak94Tk5xSUd2VEprUFlvUQ?oc=5","date":"2024-11-08","type":"pipeline","source":"Psychiatrist.com","summary":"Dysregulation of Noradrenergic Activity: Its Role in Conceptualizing and Treating Major Depressive Disorder, Schizophrenia, Agitation in Alzheimer’s Disease, and Posttraumatic Stress Disorder - Psychi","headline":"Dysregulation of Noradrenergic Activity: Its Role in Conceptualizing and Treating Major Depressive Disorder, Schizophren","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxON2FQZnpXejFzdzJncGlDQWI5VVR0Q0c0LUpVTkViQjR3aXZMblNELTRVanFWakh3ajljYTJmbGNreXN5VDZ3bHNERzF1SjliUGhWVDhvY0RLTXBXZHFGcnBwTDlEQ2RCdTAya1NqLTRnaTRlUmhHMS04N3d4M3ZOS1prWmJDdw?oc=5","date":"2024-10-17","type":"pipeline","source":"Medscape","summary":"MDMA Is Off the Table, So What’s Next for PTSD? - Medscape","headline":"MDMA Is Off the Table, So What’s Next for PTSD?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE40ZldVVndOYTRIWV91Mmx2SzNWMTRSMElhNWhUVEkwRzVtdTZrUTNPWWV1bGUxNm1leGRsR2pGSzlORWZtTU9ZeEtGdFB0d3RocDM0MWtiSXNCVElCckwtMUJ3YlIyWWQ3V1BHT09hRk1Bdw?oc=5","date":"2023-07-25","type":"trial","source":"Psychiatry Online","summary":"Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report - Psychiatry Online","headline":"Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Imp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5QWlZIa3ZVbk5CZW9nbHUwMW5LeTVyV3NRams3bFdETDNuV3Zvb083QkhEZ3U4YTlyXzlVMzBldFpvMEZzdEhIY3U2cGVHNVh4eHdJSFBuc1JfNGFLS3VjNWstcW9VQ0ZqSmc?oc=5","date":"2023-07-19","type":"trial","source":"Wiley Online Library","summary":"Comorbid alcohol use disorder and posttraumatic stress disorder: A proof-of-concept randomized placebo-controlled trial of buprenorphine and naltrexone combination treatment - Wiley Online Library","headline":"Comorbid alcohol use disorder and posttraumatic stress disorder: A proof-of-concept randomized placebo-controlled trial ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOSmRscDJvTVBBQkE1U1JtaHRzV3dYclZ2Y0IwQkVYYVRnZHBiTkh6WE1KR2xWZjBKZXdVUVlJdnN5TGlDbWd2MWxZWDBPRTctYXItbWlFZHYtdnRjOVdyaHduVjhXM1N1dHJBaDNNcE1xaU1KN041M2VIMDQ5VlIwZ3hiTmM2cVNCVnloX3V0THVEM1U4NVlhQ3lsZUhGZnpoZ3JtVlhMUTRTRVZBUGhBUzh2dWE?oc=5","date":"2022-04-25","type":"pipeline","source":"Psychiatrist.com","summary":"The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective - Psychiatrist.com","headline":"The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE93S0d3Q0xwSVZvYV80WnV0Y0VFTFFINEhtNWNVSUlCRVN0dy1KQWpDMTF0RzNVczNkX1djSmd2NUFMTHBQT21tN0wyby1HekxEQllETy11RUFra29lN0JEeXp1bUlFRG52Q3NlYTBNTVY?oc=5","date":"2019-04-05","type":"pipeline","source":"Psychiatry Online","summary":"General Predictors and Moderators of Depression Remission: A VAST-D Report - Psychiatry Online","headline":"General Predictors and Moderators of Depression Remission: A VAST-D Report","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}